Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Gilead Sciences Reports Strong Cure Rate for Hepatitis C Drug


New data is significant as the biotech company moves closer to filing for approval of its drug sofosbuvir next year. In a late-stage study, Gilead's drug showed an almost 80% cure rate in a tough-to-treat patient group.

MINYANVILLE ORIGINAL Gilead Sciences (NASDAQ:GILD) took another step forward with its hepatitis C drug program Tuesday, showing a strong cure rate for hard-to-treat patients in a late-stage study. The data met Wall Street expectations and is significant because it is the first of several trials in the final round -- or so-called Phase III stage -- of study necessary to win US approval.

The company is expected to announce three more Phase III trial results in the first quarter of 2013 and will likely file for US Food and Drug Administration approval for its drug, sofosbuvir, by the middle of next year. Based on Tuesday's results and earlier study data, analysts predict that Gilead's drug is a winner. A number of investors are betting that way as well. Gilead shares are up more than 90% in the past 12 months, trading at $75.25 midday Tuesday.

The latest data showed that 78% of study patients with chronic hepatitis C remained free of the virus 12 weeks after completing a regimen of sofosbuvir and the older drug ribavirin. The study included patients who cannot tolerate or who are ineligible or unwilling to receive the injected drug interferon. Despite the approval last year of breakthrough drugs made by Vertex Pharmaceuticals (NASDAQ:VRTX) and Merck (NYSE:MRK), the standard of care for the liver-destroying virus still requires interferon, which carries nasty, flu-like side effects. The goal of Gilead, Abbott Laboratories (NYSE:ABT), and others is to develop an all-oral regimen that cuts out the need for interferon. The Gilead drug appears to do that effectively.

"Achieving a sustained virologic response in three quarters of patients is an impressive result for a sofosbuvir-based, all-oral treatment in a group of individuals for which no suitable alternative therapy exists," says Gilead Chief Scientific Officer Norbert Bischofberger in a statement.

The just-announced results are for a study that only included patients with a certain genetic makeup -- genotype 2 or 3, which represents about one third of all hepatitis C patients, according to ISI Group analyst Mark Schoenebaum.

Gilead is also testing its drug for the more common genotype 1 patient and it is also studying the use of its drug without ribavirin. The FDA application Gilead is expected to file next year would be just the first as the company will seek additional indications for the treatment. What's important is that an all-oral treatment gives Gilead (or a rival company) the opportunity to transform the market for these type of treatments.

"The results seen to date with sofosbuvir (with or without other agents) look promising, and we continue to believe this agent could be an effective backbone therapy for the treatment of hepatitis C," William Blair analyst John Sonnier says.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos